We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesTharimmune Inc.

Tharimmune Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2026-05-21T21:49:36.423552Z
Market Cap
1.18M

Momentum Score

…

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
4.15
Low
163.12
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-194.12%
Net Debt
-10.94M
ROCE
-75.37%
Diluted EPS TTM
-15.50

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -8.47M -2.21M -2.42M -1.53M
Net income -8.47M -2.21M -2.42M -1.53M
Selling general administrative 4.60M 1.37M 0.67M 0.63M
Ebit -6.88M -3.21M -1.52M -0.99M
Operating income -6.88M -3.21M -1.52M -0.99M
Interest expense 1.59M 0.83M 0.25M 0.08M
Net interest income -1.59M -0.83M -0.25M -0.08M
Total revenue 0.00M 0.00M 0.00M 0.00M
Total operating expenses 6.88M 3.21M 1.52M 0.99M
Total other income expense net - 1.83M -0.65M -0.46M
Net income from continuing ops -8.47M -2.21M -2.42M -1.53M
Net income applicable to common shares -8.47M -2.21M -2.42M -1.53M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 10.95M 6.69M 0.62M 0.29M 0.04M
Other current assets 0.01M 0.18M 0.55M 0.10M 0.00M
Total liab 1.82M 1.14M 5.31M 4.01M 1.66M
Total stockholder equity 9.13M 5.54M -4.68M -3.72M -1.62M
Other current liab 0.91M - 0.98M 1.33M 0.13M
Common stock 0.00M 0.00M 0.00M 0.00M 0.02M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -24.70M -15.38M -6.91M -4.70M -2.09M
Cash 10.94M 6.51M 0.00M 0.19M 0.04M
Total current liabilities 1.82M 1.14M 4.53M 2.73M 1.13M
Net debt -10.94M - 2.16M 1.66M 0.93M
Short long term debt - - 1.39M 0.56M 0.43M
Other stockholder equity 33.83M - - - -
Total current assets 10.95M 6.69M 0.62M 0.29M 0.04M
Net tangible assets - 5.54M -4.68M -3.72M -1.62M
Long term debt - - 0.77M 1.29M 0.53M
Accounts payable 0.91M 0.95M 1.46M 0.51M 0.24M
Non current assets total 0.00M 0.00M 0.00M 0.00M 0.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Change to liabilities -0.14M 0.58M 0.31M -0.03M
Net borrowings -0.01M 1.08M 1.23M 0.58M
Total cash from financing activities 13.06M 0.90M 1.23M 0.71M
Change to operating activities -0.43M 0.47M 0.00M 0.27M
Net income -8.47M -2.21M -2.42M -1.53M
Change in cash 6.51M -0.19M 0.15M 0.00M
Begin period cash flow 0.00M 0.19M 0.04M 0.04M
End period cash flow 6.51M 0.00M 0.19M 0.04M
Total cash from operating activities -6.56M -1.09M -1.08M -0.71M
Issuance of capital stock 13.65M - - -
Sale purchase of stock -0.07M - - -
Other cashflows from financing activities -0.52M -0.18M -0.18M -0.18M
Change to netincome 0.92M -0.59M 0.89M 0.55M
Capital expenditures 0.00M 0.00M 0.00M 0.00M
Change in working capital -0.57M 1.05M 0.31M 0.24M
Stock based compensation 0.80M 1.24M 0.23M 0.09M
Other non cash items 1.68M -1.17M 0.80M 0.48M
Free cash flow -6.56M -1.09M -1.08M -0.71M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Tharimmune Inc.

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

1200 Route 22 East, Bridgewater, NJ, United States, 08807

908 955 3140

https://www.tharimmune.com

2

Name Title Year Born
Mr. Randy D. Milby MBA President, Chairman & CEO 1954
Mr. Sireesh Appajosyula Pharm.D. COO & Director 1976
Mr. Thomas P. Hess CPA, MBA Chief Financial Officer 1964

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…